Company achieved significant milestones including transition to clinical-stage with Phase 1 trial initiation, successful advancement of multiple pipeline candidates (IBIO-600, IBIO-610, IBIO-800), substantial capital raises ($126 million total), extended cash runway to fiscal 2028, and strengthened leadership team. Preclinical data supports differentiated therapeutic potential for obesity and cardiometabolic diseases.
Also mentions IBIO
Articles that tag IBIO but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
